PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experience Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundation KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise Tor
Biotechnologies, Pharmaceutique
2026-07-21 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, an
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-21 7:00 AM EDT | Phio Pharmaceuticals Corp.
Restart Life Sciences Details U.S. E-Commerce Launch, AI Platform, and Three-Phase Expansion Strategy for Holy Crap Foods
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is providing a corporate update regarding its upcoming expansion into the United States, the launch of an updated AI-driven e-commerce platform, and pipeline developments for its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"). The Company remains focused on scaling operations, driving revenue generation, and
Technologies, Biotechnologies, Santé
2026-07-21 6:00 AM EDT | Restart Life Sciences Corp.
Bachem Plans to Build a Large-Scale Production Facility in Sisslerfeld
Bubendorf, Switzerland--(Newsfile Corp. - July 21, 2026) - Bachem (SIX: BANB) announced today the sig
Biotechnologies, Produits chimiques, Soins de santé et hôpitaux, Pharmaceutique
2026-07-21 12:40 AM EDT | Bachem Holding AG
CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research
Houston, Texas--(Newsfile Corp. - July 20, 2026) - Alzheimer's disease is not only a scientific challenge; it is a human crisis affecting millions of patients, families, caregivers, and healthcare systems. Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) is responding through an intranasal nanoemulsion platform designed to explore new possibilities in neurodegenerative care through cannabinoid-based and natural-compound science. CBIH's invention centers on an intranasal me
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-07-20 7:00 AM EDT | Cannabis Bioscience International Holdings
Trenchant Technologies Capital Corp. Announces Delay of Annual Filings and Application for MCTO Application
Vancouver, British Columbia--(Newsfile Corp. - July 17, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTC Pink: AITTF) ("Trenchant" or the "Company") announces that it will be delaying the filing of its audited annual financial statements for the year ended March 31, 2026, the related management's discussion and analysis, and related CEO and CFO certificates (collectively, the "Required Filings") beyond the July 29, 2026 filing deadline. The delay is res
Technologies, Services bancaires / financiers, Biotechnologies, Soins de santé et hôpitaux
2026-07-17 4:50 PM EDT | Trenchant Technologies Capital Corp.
Marvel Biosciences Announces Private Placement for up to $3.0 Million
Calgary, Alberta--(Newsfile Corp. - July 16, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non‐brokered private placement offering (the "Offering") of units of the Company ("Units") at a price of $0.15 per Unit. The Offering will be for a minimum of 10,000,000 Units for gross proceeds of $1,500,000, and up a maximum of 20,000,000 Units, for gross proceeds of up to
2026-07-16 4:00 PM EDT | Marvel Biosciences Corp.
Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the 3D analysis of telomeres (which are the ends of chromosomes), announced positive interim results from an ongoing retrospective clinical study conducted in collaboration with National and Kapodistrian University of Athens. The clinical trial, which i
2026-07-16 7:00 AM EDT | Telo Genomics Corp.
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, today provided a corporate update outlining its strategic focus on personalized medicines, specifically peptides and psychedelics. PharmaTher believes peptides and psychedelics are gaining strong momentum and plans to capitalize on this opportunity using its MEDBOTX™ 3D-printi
Biotechnologies, Pharmaceutique
2026-07-15 8:00 AM EDT | PharmaTher Holdings Ltd.
Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it is arranging a non-brokered private placement to raise gross proceeds of up to C$1,365,000 (the "Offering"). The Offering will consist of common shares in the capital of the Company (the "Common Shares") priced at not less than C$0.91 per Common Share. The Company expects the
2026-07-15 8:00 AM EDT | Sharp Therapeutics Corp.
BioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 15, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) grant. This non-dilutive funding will support a new research initiative at BioHar
Biotechnologies, Pharmaceutique, Santé
2026-07-15 7:30 AM EDT | BioHarvest Sciences Inc.
Years of Preparation. One Regulatory Approval. Commercial Launch Begins: CBIH Receives Texas License for Consumable Hemp Products
Houston, Texas--(Newsfile Corp. - July 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that the State of Texas has approved the Company's license to manufacture and distribute consumable hemp products. This approval turns years of vision, science, and preparation into action and marks the moment CBIH steps into the market and begins commercial distribution. The Company e
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-07-15 7:00 AM EDT | Cannabis Bioscience International Holdings
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today significant progress in the protection of its proprietary innovations across key international markets. The company has received multiple favorable patent actions encompassing three
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-15 7:00 AM EDT | Phio Pharmaceuticals Corp.
Trenchant Technologies Capital Corp. Announces Closing of First Tranche of the Private Placement of Convertible Debentures
Toronto, Ontario--(Newsfile Corp. - July 14, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTC Pink: AITTF) ("Trenchant" or the "Company") is pleased to announce that, further to its news release of July 03, 2026, that it has closed a first tranche on July 10, 2026 (the "First Tranche") of its private placement (the "Offering"), and has issued 500 debentures (the "Debentures") for gross proceeds of $500,000. Trenchant anticipates closing the rema
Technologies, Services bancaires / financiers, Biotechnologies, Soins de santé et hôpitaux
2026-07-14 8:13 PM EDT | Trenchant Technologies Capital Corp.
Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - July 14, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. The Stage 1 cohort demonstrated a mean Consonant-Nucleus-Consonant ("CNC") word recognition
Biotechnologies, Soins de santé et hôpitaux
2026-07-14 9:17 AM EDT | Envoy Medical, Inc.
Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide a strategic operational update regarding its collaboration with the Richardson Centre for Food Technology and Research (RCFTR) at the University of Manitoba. Following the recent unveiling of its newly formulated product roadmap, targeted to capitalize on emerging consumer shopping patterns, the Comp
Technologies, Biotechnologies, Santé
2026-07-14 6:00 AM EDT | Restart Life Sciences Corp.
Nextleaf Evolves Glacial Gold, Building Trust with Wellness Consumers
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to announce the evolution of Glacial Gold, the Company's flagship consumer cannabis brand. The most significant evolution in Glacial Gold's history, a milestone that reflects Nextleaf's continued development into a consumer-packaged goods ("CPG") comp
Biotechnologies, Pharmaceutique, Cannabis, Extracteurs de cannabis
2026-07-13 9:29 AM EDT | Nextleaf Solutions Ltd.
BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on July 22, 2026.
Biotechnologies, Pharmaceutique, Santé
2026-07-13 8:00 AM EDT | BioHarvest Sciences Inc.
TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering over 1 Million Lives
Highlights Meuhedet Health Services, Israel's third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed's flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now accepted by two of Israel's four national HMOs—Maccabi Healthcare Services and Meuhedet—providing institutional access to approximately four million insured
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-07-09 7:00 AM EDT | TempraMed Technologies Ltd.
Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma
Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced that it has filed a U.S. provisional patent application seeking to protect a new TeloView® biomarker algorithm for use with liquid biopsy samples, even those with minimal residual disease ("MRD") in the management of patients with multiple myeloma ("MM"). "
2026-07-09 7:00 AM EDT | Telo Genomics Corp.